Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 10
Submit an article Journal homepage
239
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Clinical value of molecular MRD monitoring by next-generation sequencing in patients with IDH2 mutated AML

Evgenii ShumilovDepartment of Hematology and Medical Oncology, University Medicine Göttingen (UMG), Göttingen, Germany;
,
Johanna FlachDepartment of Hematology and Oncology, Medical Faculty Mannheim of the Heidelberg University, Mannheim, Germany;
,
Raphael JoncourtUniversity Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland;
,
Naomi PorretUniversity Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland;
,
Gertrud WiedemannUniversity Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland;
,
Urban NovakDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland;
,
Eva GfellerUniversity Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland; ;Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland
,
Barbara JekerDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland;
,
Ursula AmstutzCenter of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, Switzerland
,
Thomas PabstDepartment of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland; Correspondence[email protected]
&
Ulrike BacherUniversity Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland; ;Center of Laboratory Medicine (ZLM)/University Institute of Clinical Chemistry, Inselspital, Bern University Hospital, Bern, SwitzerlandCorrespondence[email protected]
 show all
Pages 2588-2590 | Received 07 Dec 2018, Accepted 10 Feb 2019, Published online: 18 Apr 2019

References

  • Bacher U, Shumilov E, Flach J, et al. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use. Blood Cancer J. 2018;8:113.
  • Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–2221.
  • Gross S, Cairns RA, Minden MD, et al. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010;207:339–344.
  • Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17:225–234.
  • DiNardo CD, Ravandi F, Agresta S, et al. Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015;90:732–736.
  • Green CL, Evans CM, Zhao L, et al. The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood. 2011;118:409–412.
  • Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130:722–731.
  • Amatangelo MD, Quek L, Shih A, et al. Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response. Blood. 2017;130:732–741.
  • Quek L, David MD, Kennedy A, et al. Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib. Nat Med. 2018;24:1167–1177.
  • Brambati C, Galbiati S, Xue E, et al. Droplet digital polymerase chain reaction for DNMT3A and IDH1/2 mutations to improve early detection of acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation. Haematologica. 2016;101:e157–e161.
  • Ferret Y, Boissel N, Helevaut N, et al. Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. Haematologica. 2018;103:822–829.
  • Debarri H, Lebon D, Roumier C, et al. IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget. 2016;6:42345–42353.
  • Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
  • Jeziskova I, Razga F, Toskova M, et al. Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene. Leuk Lymphoma. 2013;54:867–870.
  • Petrova L, Vrbacky F, Lanska M, et al. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring? Clin Biochem. 2018;61:34–39.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.